Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Proteomic detection of cancer in asbestosis patients using SELDI-TOF discovered serum protein biomarkers.

Authors
Tooker-BC; Newman-LS; Bowler-RP; Karjalainen-A; Oksa-P; Vainio-H; Pukkala-E; Brandt-Rauf-PW
Source
Biomarkers 2011 Mar; 16(2):181-191
NIOSHTIC No.
20039346
Abstract
OBJECTIVES: To identify biomarkers for cancer in asbestosis patients. METHODS: SELDI-TOF and CART were used to identify serum biomarker profiles in 35 asbestosis patients who subsequently developed cancer and 35 did not develop cancer. RESULTS: Three polypeptide peaks (5707.01, 6598.10, and 20,780.70 Da) could predict the development of cancer with 87 percent sensitivity and 70 percent specificity. The first two peaks were identified as KIF18A and KIF5A, respectively, and are part of the Kinesin Superfamily of proteins. CONCLUSIONS: We identified two Kinesin proteins that can be potentially used as blood biomarkers to identify asbestosis patients at risk of developing lung cancer.
Keywords
Cancer; Biomarkers; Asbestosis; Blood-serum; Pathology; Disease-incidence; Peptides; Proteins; Lung; Lung-cancer; Risk-factors; Author Keywords: Disease progression; CART analysis; serum
Contact
Brian C. Tooker, Division of Allergy and Clinical Immunology, University of Colorado Denver, Building: RC2, Mail Stop: B164, 12700 E. 19th Ave, Aurora, CO, 80045
CODEN
BIOMFA
CAS No.
1332-21-4
Publication Date
20110301
Document Type
Journal Article
Email Address
Brian.Tooker@ucdenver.edu
Funding Amount
163500
Funding Type
Grant
Fiscal Year
2011
NTIS Accession No.
NTIS Price
Identifying No.
Grant-Number-R01-OH-004192; Grant-Number-R01-OH-007590
Issue of Publication
2
ISSN
1354-750X
Source Name
Biomarkers
State
IL; CO
Performing Organization
University of Illinois
TOP